In This Article:
J&J JNJ recently reported new positive data from the phase III MARIPOSA study, which compared the combination of Rybrevant and Lazcluze against AstraZeneca’s AZN Tagrisso in first-line EGFR-mutated non-small cell lung cancer (“NSCLC”).
Data from the study suggests that the Rybrevant-Lazcluze combo significantly extends overall survival (“OS”) in NSCLC patients with EGFR exon 19 deletions (ex19del) or exon 21 L858R substitution (L858R) mutations.
At a median follow-up of 37.8 months, patients on J&J’s combo therapy showed longer survival, with median OS not yet reached. In contrast, patients treated with the AstraZeneca drug achieved a median OS of 36.7 months. Notably, 56% of patients treated with J&J’s combo therapy were alive at 3.5 years compared with 44% on AstraZeneca’s drug. This data suggests continued benefit of J&J’s therapy over time, based on which study investigators expect that the combo can extend OS by at least a year over Tagrisso.
We remind investors that the MARIPOSA study already achieved its primary endpoint of statistically significant and clinically meaningful improvement in progression-free survival. Based on this data, J&J secured approval for the Rybrevant-Lazcluze combo in the above indication in the United States and European Union (“EU”) last year.
J&J Boasts Rybrevant-Lazcluze Combo as Next Standard of Care
Through this latest data, J&J intends to take the crown from the AstraZeneca drug, which is the current standard of care for EGFR-mutated NSCLC. However, Tagrisso’s convenience as a once-daily pill remains a major advantage. In contrast, J&J’s regimen requires intravenous infusions, adding a layer of complexity that could limit adoption.
A key step for J&J will be securing FDA approval for a subcutaneous version of Rybrevant, which would significantly reduce administration time. However, the company’s initial attempt was rejected in December due to manufacturing concerns. Until this hurdle is cleared, Tagrisso’s ease of use may keep it the preferred option for doctors and patients.
Recent Developments Related to JNJ's Rybrevant
Last month, the EMA’s Committee for Medicinal Products for Human Use issued a positive opinion recommending approval for a subcutaneous version of Rybrevant combined with Lazcluze in the first-line EGFR-mutated NSCLC indication. A final decision is expected later this year.
In September, the FDA approved the combination of Rybrevant and standard-of-care chemotherapy (carboplatin and pemetrexed) for treating adult patients with advanced NSCLC with EGFR ex19del or L858R mutations after failure of prior therapy, including an EGFR-TKI. This combination received approval for a similar use in the EU last year.